Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
Public Health England (PHE) has released advice for smokers and vapers that could be used by healthcare professionals to encourage patients to quit smoking in light of the COVID-19 outbreak. Based on mixed and developing evidence, PHE released the advice which could be used as part of Very Brief Advice (VBA) approaches to support patients. PHE advises...
PSNC is urging community pharmacy teams to report issues obtaining stock due to drug quota restrictions applied by wholesalers or manufacturers to assist with our representation of these issues to the Department of Health and Social Care (DHSC), the Healthcare Distribution Association (HDA) and the Association of the British Pharmaceutical Industry (ABPI). The PSNC Dispensing...
Department of Health and Social Care (DHSC) has today (29/05/2020) set the FINAL price concessions for May 2020. The new additions to the May 2020 price concession list are below: Drug Pack size Price Concession Carbocisteine 375mg capsules 120 £6.87 Clarithromycin 250mg/5ml oral suspension 70ml £8.60 Clonidine 25microgram tablets 112 £13.62 Duloxetine 20mg gastro-resistant capsules...
The PSNC Committee met virtually last week, holding detailed discussions on which activities community pharmacies should stop, start or continue to do in the current and coming environment. Immediate priorities such as the NHS Flu Vaccination Service were considered as well as the role that pharmacies could play in future COVID-19 services such as testing....
Update – availability now expected to be: 100mg/25mg/200mg – Mid July 2020 150mg/37.5mg/200mg – Early August 2020 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Stanek® (levodopa/carbidopa/entacapone) tablets – various strengths Stanek® tablets (various strengths) are out of stock. The anticipated re-supply dates range between mid June 2020...
Update 29/05/2020 Availability now expected to be w/c 15th June 2020 Department of Health and Social Care (DHSC) has issued a medicine supply disruption alert for Salazopyrin® (sulfasalazine) 500mg suppositories. Alert reference: SDA/2020/008 There is a supply issue affecting Salazopyrin® 500mg suppositories due to an increase in demand seen by the sole supplier, Pfizer. Salazopyrin®...
Update – 29/05/2020 Availability now expected June 2020 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Phytomenadione (Konakion MM Paediatric) 2mg/0.2ml ampoules . Konakion MM Paediatric is out of stock. The anticipated re-supply date is the end of May 2020. When prescribing a product that is not licensed in...
Update (29/05/2020): resupply dates now expected: 25mg and 50mg – Mid June 2020 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Promazine 25mg and 50mg tablets Promazine 25mg and 50mg tablets are out of stock. The anticipated re-supply date is mid April 2020 The DHSC Medicine Supply Team...
Update (29/05/2020): resupply dates now expected: 250mg – early July 2020 500mg – in stock Department of Health and Social Care (DHSC) has issued a medicine supply notification for Valproate semisodium (Depakote) 250mg and 500mg tablets Depakote 500mg tablets are out of stock until early April 2020 Depakote 250mg tablets will be out of stock...
Update (29/05/2020): resupply dates now expected: Famotidine 20mg tablets have limited availability with no confirmed date of next supply (Tilomed and Teva) Famotidine 40mg tablets have limited availability with no confirmed date of next supply (Tilomed) June 2020 (Teva) Cimetidine 200mg tablets are in stock (Ennogen) no confirmed resupply date (Medreich) Cimetidine 400mg tablets are...
Summary list of field safety notices (FSNs) from medical device manufacturers from 27 to 29 May 2020
Anyone supplying these types of tests should temporarily stop this service.
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
The number of applications pending, refused and granted for the early access to medicines scheme (EAMS).
You must get permission to export certain drugs and medicines.
How to get fast-track approval of medical devices during COVID-19.
The different types of tests and testing kits for COVID-19, and the specifications for manufacturers.
Good clinical practice (GCP) referrals received by the MHRA for 2011 to 2018.
Summary list of field safety notices (FSNs) from medical device manufacturers from 18 to 22 May 2020
Keep up to date with the latest information from the UK GLP monitoring authority.
Torbay Pharmaceuticals has informed us that the carton label on Sodium Benzoate (Amzoate) 2g in 10 mL Sterile Solution for injection incorrectly states the concentration of disodium edetate (excipient) as 0.1% w/v (10mg in 1mL) instead of 0.1% w/v (10mg in 10mL).
These temporary good manufacturing practice (GMP) flexibilities will be allowed to address the current exceptional circumstances
As a precautionary measure, Pfizer Limited is recalling the above batches from wholesalers due to out of specification results from the ongoing stability studies. An evaluation of the foil laminate pouch identified oxygen levels above the specified limits, resulting in lower dissolution results for bazedoxifene acetate.
MHRA has today given the first positive scientific opinion under the Early Access to Medicines Scheme (EAMS) for use of Gilead’s remdesivir.
EAMS scientific opinion issued to Gilead Sciences Ltd for remdesivir in the treatment of patients hospitalised with suspected or laboratory-confirmed SARS-CoV-2 infection who meet the clinical criteria
Information for clinicians and patients.
How to show MHRA you're meeting good clinical practice (GCP) standards and what to expect from an inspection.
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor the Commission on Human Medicines.
Reporting to the new site will enable the MHRA to rapidly identify new and emerging side effects and medical device incidents in COVID-19 treatment, including side effects for medicines taken by patients to manage long-term or pre-existing conditions.
Guidance has been published to support initiation of valproate in female patients and for annual review and pregnancy testing during the coronavirus pandemic.
This strategy sets out Defra’s equality, diversity and inclusion priorities from 2020 to 2024.
Guidance on applying for an authorisation to manufacture veterinary medicines.
You must get permission to export certain drugs and medicines.
News and guidance on veterinary medicines issues affected by coronavirus (COVID-19).
Relaxation of enforcement during the coronavirus (COVID-19) outbreak.
Temporary change to the standard VMD guidance on Manufacturers of extemporaneous preparations for use under the cascade (ManSA).
Relaxation of enforcement during the coronavirus (COVID-19) outbreak
Relaxation of enforcement during the coronavirus (COVID-19) outbreak.
Enforcement of Veterinary Medicines Regulations relaxed in light of enhanced precautions required by the response to coronavirus (COVID-19).
Request to not send post to the VMD office.
Residues of veterinary medicines in food 2020 surveillance results.
Residues of veterinary medicines in food 2019 surveillance results.
The VMD virtual office will be closed on Monday 25 and Tuesday 26 May.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Marketing Authorisation Holders (MAHs) have informed the VMD of supply problems with the following lactating cow intramammary antibiotics.
For a marketing authorisation holder only; how to report a defect with a veterinary medicine.
Changes to exemptions from the Veterinary Medicines Regulations (VMR) for small pet animals (known as Schedule 6 exemptions).
How to comply with the exemption from the Veterinary Medicines Regulations that allow certain animal medicines to be sold without an authorisation.
Marketing Authorisations Information Service (MAVIS) Hub edition 114
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ
Genetic ‘barcoding’ in GP surgeries can identify men at higher risk of prostate cancer, researchers claim
The NHS Race and Health Observatory will be hosted by the NHS Confederation
The trial is unlikely to show a statistically significant improvement in invasive disease-free survival
The vaccine could be Janssen's first to win EU approval
The Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent the the risk of disease recurrence or death by around 80%
The adjuvant could reduce the amount of vaccine protein required per dose and enhance the immune response
The treatment for pancreatic inflammation has been shown in the lab to prevent COVID-19 from entering human cells
The trial will test the potential of combining an antiviral with an immune modulator
The 'game-changing' results will likely result in a paradigm shift in current clinical practice, researchers said
LYT-100 employs a multimodal mechanism of action to potentially reduce, delay or prevent the lung dysfunction documented in COVID-19 patients
Researchers are hopeful that this 'ground-breaking approach' could accelerate the prediction of which patients are more at risk of their disease returning
The drug giant agreed a new price for Tecentriq with NHS England and Improvement
Anyone who tests positive for coronavirus will be contacted by NHS Test and Trace and will need to share information about their recent interactions
The Defeat Diabetes includes a number of initiatives to provide access to affordable care to vulnerable patients and accelerate prevention to halt the rise of the disease
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
